Orphan-drug designation does not automatically block approval of every later use of a drug. FDA generally ties seven-year orphan-drug exclusivity to the use or indication actually approved. But in Catalyst Pharmaceuticals, Inc. v. Becerra, the Eleventh Circuit read the statute more broadly: exclusivity covered the entire rare disease or condition named in the designation, even when the first approval covered a narrower patient group. That conflict matters when the same drug may treat different populations with the same rare disease.
What orphan-drug designation means—and what it does not
Under the Orphan Drug Act, a rare disease or condition generally means one affecting fewer than 200,000 people in the United States, or one affecting more people when development costs are not reasonably expected to be recovered from U.S. sales. A sponsor may seek orphan designation while developing a drug for such a condition. Designation can make the sponsor eligible for incentives, including potential tax credits for qualified clinical trials and exemption from certain user fees.
Designation is not FDA approval, however. It does not authorize a company to market the drug, establish that the drug is safe or effective, or guarantee that FDA will approve a future application. FDA describes designation and approval or licensure as separate processes in its orphan-product designation overview.
When the seven-year exclusivity period begins
The statutory protection is not triggered just because FDA grants designation. For a qualifying designated drug, the seven-year period begins after FDA approves the drug application or licenses the biologic. During that period, the statute generally bars FDA from approving another application for the same drug for the same rare disease or condition, subject to exceptions. The statutory excerpts published by FDA identify exceptions where the original holder consents or FDA determines that the holder cannot assure sufficient quantities of the drug.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
The dispute is about how broadly to read “same rare disease or condition.” FDA’s longstanding regulatory approach generally connects exclusivity to the approved use or indication. That leaves room for a different company to seek approval of the same drug for another population or use within the broader disease, provided it meets the applicable requirements. The Congressional Research Service summarized this approach and the legal conflict in its March 5, 2024 overview of orphan-drug exclusivity.
FDA’s indication-specific approach versus the Catalyst ruling
The Eleventh Circuit issued its decision in Catalyst Pharmaceuticals, Inc. v. Becerra on September 30, 2021. It held that the statutory bar applies across the entire disease or condition for which a drug was designated, even if FDA initially approved the drug for only a narrower population. The court’s reading therefore differs from FDA’s interpretation, which limits the bar to the same approved use or indication.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
| Question | FDA’s general approach | Eleventh Circuit’s Catalyst reading |
|---|---|---|
| What does exclusivity cover? | The same approved use or indication; another use within the disease may be eligible for a separate application, as described in the CRS’s March 5, 2024 overview. | The entire designated disease or condition, even if the first approval covers a narrower population, as explained in FDA’s overview of Catalyst. |
| What happens in FDA’s cystic-fibrosis example? | Exclusivity for one approved patient group does not, under FDA’s view, automatically bar a distinct use for another cystic-fibrosis population. | If designation covered cystic fibrosis but approval covered adults with a particular mutation, the same drug could be barred from approval for other cystic-fibrosis populations during the exclusivity period. |
| Geographic reach | FDA’s regulatory interpretation is the agency’s general approach. | The decision is an Eleventh Circuit appellate ruling; it should not be described as automatically establishing a nationwide rule. |
The practical consequence is uncertainty for developers, patients, and clinicians: the answer to whether another use can be approved may depend on which legal interpretation controls, the exact designation and approved label, and the status of the exclusivity period. The CRS overview is dated March 5, 2024; it does not establish whether later legislation or court decisions have changed the landscape. A current decision involving a particular drug requires checking later authority and that drug’s FDA exclusivity record.
Can another company get approval for a different use?
Under FDA’s indication-specific approach, a different population or use within the same disease may be pursued through the relevant FDA application process; orphan designation alone does not make such an application approvable. The Catalyst ruling points the other way for the Eleventh Circuit’s reading: if the drug is the same and the disease matches the designation, a narrower first label does not necessarily leave other patient groups open during the seven-year term.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
Where a sponsor seeks orphan designation for the same drug and same rare disease as an already-approved drug, FDA guidance may require a plausible hypothesis of clinical superiority. The agency describes possible bases as greater effectiveness, greater safety for a substantial portion of the target population, or, in unusual circumstances, a major contribution to patient care. For the latter, FDA identifies factors such as treatment location or duration, comfort, treatment burden, ease of administration, dosing interval, and potential self-administration; it says cost is not considered for this determination. These are designation and exclusivity considerations, not a promise of marketing approval. See FDA’s designation FAQ.
How to assess a specific drug dispute
Do not rely on the label “orphan drug” alone. The relevant facts are specific, and several protections may overlap without covering the same thing.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
- Compare the designation and label. Identify the disease or condition named in the orphan designation, then compare it with the exact FDA-approved indication and patient population.
- Check whether it is the same drug. The statutory question concerns the same drug; a different product or active moiety can raise a different analysis.
- Establish the timing. Confirm the qualifying approval or licensure date and the remaining portion of the seven-year term, rather than counting from designation.
- Identify the controlling legal context. The Eleventh Circuit decision should not be assumed to dictate the result everywhere; later court decisions, legislation, FDA rules, and guidance can matter.
- Check statutory exceptions and other protections. Consent or an inability-to-assure-sufficient-supply finding can affect the statutory bar. Separately assess patents and any other regulatory exclusivities.
Orphan exclusivity is not a patent
Orphan-drug exclusivity is a statutory FDA approval bar with a defined trigger, scope, and exceptions. A patent is a property right granted by the U.S. Patent and Trademark Office. Patents and regulatory exclusivities may overlap or run on different schedules, and they may protect different aspects of a product. A patent’s existence does not itself establish orphan exclusivity, and the end of orphan exclusivity does not necessarily mean that all patent barriers have ended. FDA explains the distinction in its patents and exclusivity FAQ.
Quick Recap
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Recommended Free Tools
